Medical Devices Regulation (EU)

Medical Devices Regulation (EU)
Title	Medical Devices Regulation (EU)
Type	Regulation
Year	2017
Number	745/2017
Adopted	5 April 2017
Commenced	26 May 2017
Applicable from	26 May 2021
Replaced	Council Directive 93/42/EEC; Council Directive 90/385/EEC
Official journal	Official Journal of the European Union

Medical Devices Regulation (EU) The Medical Devices Regulation adopted by the European Parliament and the Council of the European Union in 2017 repealed and replaced earlier Council directives to strengthen the legal framework for medical devices across the European Union. It established harmonised rules on safety, performance, conformity assessment, market surveillance and clinical evidence for devices placed on the European Single Market. The regulation interacts with other instruments such as the In Vitro Diagnostic Regulation (EU) 2017/746, the General Data Protection Regulation, and decisions of the Court of Justice of the European Union.

Background and Legislative Context

The regulation emerged from high‑profile incidents and policy reviews involving Poly Implant Prothèse (PIP) scandal, debates in the European Parliament, and reports from the European Commission and the European Directorate for the Quality of Medicines & HealthCare that exposed weaknesses in the earlier Council Directive 93/42/EEC and Council Directive 90/385/EEC. Negotiations involved stakeholders including the European Council, national competent authorities such as Germany’s Federal Institute for Drugs and Medical Devices, and advocacy groups represented in hearings before the Committee on the Environment, Public Health and Food Safety. Adoption followed trilogue discussions among the European Commission, the European Parliament, and the Council of the European Union and was informed by positions from the European Economic and Social Committee.

Scope and Definitions

The regulation defines "medical device" and expands classification rules affecting products from simple devices to complex implantable systems, aligning definitions with stakeholders such as the World Health Organization and standards bodies like the European Committee for Standardization and the International Organization for Standardization. It covers manufacturers based in Member States including Germany, France, Italy, and Spain and applies to devices sold within the European Free Trade Association states that participate in the European Single Market. The text clarifies boundary issues with products regulated under the Medicinal Products Directive and the Biocidal Products Regulation, and addresses software as a medical device referenced in guidance from the European Medicines Agency.

Conformity Assessment and CE Marking

The regulation revises conformity assessment pathways and technical documentation requirements for CE marking, affecting conformity procedures overseen by Notified Bodies designated under member state authorities such as the Medicines and Healthcare products Regulatory Agency and the Agence nationale de sécurité du médicament et des produits de santé. Manufacturers must compile a technical file, a clinical evaluation, and a quality management system consistent with standards from the International Electrotechnical Commission and the International Organization for Standardization. The regulation increased clinical evidence obligations which drew scrutiny from organizations including the European Society of Cardiology and the European Association of Medical Devices Notified Bodies.

Notified Bodies and Oversight

Designation and monitoring of notified bodies fall under national authorities including Bundesinstitut für Arzneimittel und Medizinprodukte, the Swedish Medical Products Agency, and the Austrian Federal Office for Safety in Health Care. The regulation tightened designation criteria and introduced unannounced assessments and coordination via the Medical Device Coordination Group, which liaises with the European Commission and national competent authorities. Concerns raised by industry associations such as MedTech Europe and unions in hearings before the Committee on Employment and Social Affairs shaped debates over capacity and designation timelines.

Post‑market Surveillance and Vigilance

Post‑market requirements introduced a reinforced vigilance framework with Unique Device Identification systems interoperable with registries curated by institutions like the European Network for Health Technology Assessment and national agencies including Haute Autorité de Santé. Manufacturers, authorised representatives and importers must maintain post‑market surveillance plans and report serious incidents to national competent authorities such as Agence nationale de sécurité du médicament et des produits de santé and the Federal Institute for Drugs and Medical Devices. The regulation’s vigilance obligations interact with clinical investigations governed by the Clinical Trials Regulation and outcomes reported in registries like those maintained by the European Medicines Agency.

Transitional Provisions and Implementation

Transitional arrangements allowed devices certified under previous directives to remain on the market for defined periods while new classifications and re‑certifications proceeded, with deadlines extended by decisions involving the European Commission and influenced by events such as the COVID‑19 pandemic. Implementation required coordination among Member States, notified bodies and stakeholders such as industry groups including MedTech Europe and patient organisations represented in the European Patients’ Forum. The regulation provided mechanisms for derogations in public health emergencies, often referenced alongside measures by agencies such as the European Centre for Disease Prevention and Control.

Impact and Criticism

The regulation increased transparency through public databases and heightened clinical evidence requirements praised by patient groups including the European Patients’ Forum and professional societies such as the European Society of Cardiology, while industry bodies like MedTech Europe, national trade associations, and some small manufacturers criticised costs, capacity constraints, and delays documented by the European Court of Auditors. Academics at institutions such as University College London and Karolinska Institutet have analysed effects on innovation, market access, and supply chains involving manufacturers in Switzerland and United Kingdom, prompting calls for further alignment between regulatory science and health technology assessment practice at bodies like the European Network for Health Technology Assessment.

Category:European Union regulation